TFMG
5年前
Tandem Diabetes Care Inc Has Huge growth potential
Jim Cramer spoke with Kim Blickenstaff, executive chairman at Tandem Diabetes Care ( TNDM ) , which posted strong earnings last week but quickly reversed, Blickenstaff blamed the sudden reversal in their shares on global uncertainty. He said Tandem has no business in China and is in "acceleration mode."
Currently, only 30% of Type 1 diabetes patients are using a pump, Blickenstaff said, leaving a lot of room for growth for Tandem. The market potential is even greater worldwide, especially in Europe as the condition continues to become a epidemic.
The chart remains bullish but maybe more confirmation required before placing a trade.
north40000
5年前
Per TNDM 8-k dated 6-09-2019:
Tandem Diabetes Care, Inc. issued a press release announcing results from two studies of the t:slim X2™ insulin pump with Control-IQ™ advanced hybrid closed loop technology. Details from the two studies, which included data from Protocol 3 of the National Institutes of Health (NIH)-funded International Diabetes Closed Loop trial (DCLP3), and interim data from the Freelife Kid AP study, were presented on June 9, 2019 at the 79th Scientific Sessions of the American Diabetes Association.
PODD technology in combination with TNDM pump for young T1-D, said to delay development of T1-D. Very early in clinical trial.
**************************
"Pediatric Scientific Data for the Omnipod Horizon System Presented at the American Diabetes Association’s 79th Scientific Sessions
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced that positive results from the most recent clinical trial of the Omnipod® Horizon™ Automated Insulin Delivery System (Omnipod Horizon System) were presented during the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco, California. The study demonstrated that the investigational Omnipod Horizon System performed well and was safe for up to four days of use in children as young as two years old with type 1 diabetes.1
The study was conducted in a supervised hotel setting under free-living conditions with unrestricted meals and daily exercise and included pediatric participants between two and six years old. The study was preceded by seven days of their usual therapy at home with continuous glucose monitoring. Study participants spent significantly less time in hyperglycemia (=250 mg/dL), spent significantly more time in the target glucose range (70-180 mg/dL), and had better overnight glycemic control compared to their usual therapy, which is in line with the positive performance observed in earlier studies including older pediatric, adolescent and adult study participants. During the study, glucose control was maintained in the target range for 73% of the time overall and 85% of the time during the overnight period. The percentage of time spent in the hypoglycemic range (<70 mg/dL) was very low, at 2.9% overall and 2.0% overnight. The investigational Omnipod Horizon System includes unique features that allow diabetes management to be customized by adjusting the target blood glucose levels and insulin delivery....[more]
ITMS
6年前
Tandem Diabetes Care Inc $TNDM Retreats, Watch This Trade Level
Tandem Diabetes Care Inc (NASDAQ:TNDM), is a leading manufacturer and developer of medical devices for people with insulin dependent diabetes using its micro-delivery technology. The stock has been pulling back since March 22, 2019 when it traded as high $74.77 a share. Since that recent pivot top, the stock has pulled back and is now trading at $60.33 a share. Traders and investors should note the gap fill window around the $50.00 level on a daily chart. This level should be solid support. There was sideways consolidation around the $50.00 area before the gap higher breakout move in late February 2019 making this a good support level when tested. At this time, the company is scheduled to report earnings on April 25, 2019.
Nick Santiago
InTheMoneyStocks
MaineMan5
7年前
I'm a long only guy, but I would think there are much better companies out there to short than this one right now. TNDM just released good preliminary numbers, has a couple catalysts on horizon, and seems to be gaining visibility as evidenced by increasing volume the last two months. Yes, it is overbought right now by just about every measure, but that doesn't mean it can't go higher, or it gets another big pop with an announcement of some kind. JMO of course. GL.